Skip NavigationSkip to Content

A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family

  1. Author:
    Desjardins, Marylin
    Arjunaraja, Swadhinya
    Stinson, Jeffrey R
    Dorjbal, Batsukh
    Sundaresan, Janani
    Niemela, Julie
    Raffeld, Mark
    Matthews, Helen F
    Wang, Angela
    Angelus, Pam
    Su, Helen C
    Mazer, Bruce D
    Snow, Andrew L
  2. Author Address

    Division of Allergy and Immunology, Department of Paediatrics, McGill University Health Centre, Montreal, QC, Canada., Meakins-Christie Laboratories of the Research Institute of the McGill University Health Centre, Montreal, QC, Canada., Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United States., Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, United States., Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD, United States.,
    1. Year: 2018
    2. Date: Dec 12
    3. Epub Date: 2018 12 12
  1. Journal: Frontiers in immunology
    1. 9
    2. Pages: 2944
  2. Type of Article: Article
  3. Article Number: 2944
  4. ISSN: 1664-3224
  1. Abstract:

    CARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-?B and T cell Anergy (BENTA). In contrast, patients carrying loss-of-function (LOF), dominant negative (DN) CARD11 mutations present with severe atopic disease. Interestingly, both GOF and DN CARD11 variants cause primary immunodeficiency, with recurrent bacterial and viral infections, likely resulting from impaired adaptive immune responses. This report describes a unique four-generation family harboring a novel heterozygous germline indel mutation in CARD11 (c.701-713delinsT), leading to one altered amino acid and a deletion of 4 others (p.His234_Lys238delinsLeu). Strikingly, affected members exhibit both moderate B cell lymphocytosis and atopic dermatitis/allergies. Ectopic expression of this CARD11 variant stimulated constitutive NF-?B activity in T cell lines, similar to other BENTA patient mutations. However, unlike other GOF mutants, this variant significantly impeded the ability of wild-type CARD11 to induce NF-?B activation following antigen receptor ligation. Patient lymphocytes display marked intrinsic defects in B cell differentiation and reduced T cell responsiveness in vitro. Collectively, these data imply that a single heterozygous CARD11 mutation can convey both GOF and DN signaling effects, manifesting in a blended BENTA phenotype with atopic features. Our findings further emphasize the importance of balanced CARD11 signaling for normal immune responses.

    See More

External Sources

  1. DOI: 10.3389/fimmu.2018.02944
  2. PMID: 30619304
  3. PMCID: PMC6299974
  4. WOS: 000453102300001

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel